Table 1 |
||
|
Characteristics of patients under study |
||
| Osteoarthritis |
Rheumatoid arthritis |
|
|
|
||
| n |
26 |
25 |
| Age, years |
71 ± 2 [55–88] |
66 ± 2 [39–84] |
| Gender, F/M |
21/5 (81/19) |
19/6 (76/24) |
| Disease duration, years§ |
5 ± 1 |
10 ± 1 |
| Erythrocyte sedimentation rate, mm/1st hr |
16.6 ± 3.2 |
35.2 ± 7.2** |
| C-reactive protein, mg/l |
6.6 ± 0.9 |
26.3 ± 7.5# |
| Rheumatoid factor positive |
1/26 (0.5) |
12/25 (48.0) |
| Lining layer, cells |
2.1 ± 0.1 |
3.9 ± 0.3## |
| Cell density, cells/mm2 |
1257 ± 121 |
1864 ± 202** |
| T cell density, cells/mm2 |
22.2 ± 4.7 |
58.8 ± 20.1 |
| CD163+ macrophage density, cells/mm2 |
54.7 ± 10.1 |
101.3 ± 20.5* |
| Vascularity, vessels/mm2 |
28.8 ± 2.9 |
31.1 ± 3.7 |
| Medication |
||
| Prednisolone |
n.a. |
19 (76.0) |
| Mean prednisolone dose, mg/d |
n.a. |
5.2 ± 0.9 |
| NSAIDs |
14/26 (54.0) |
20/25 (80.0) |
| Methotrexate |
n.a. |
4/25 (16.0) |
| Leflunomide |
n.a. |
8/25 (32.0) |
| Azathioprine |
n.a. |
1/25 (4.0) |
| Sulfasalazine |
n.a. |
1/25 (4.0) |
| Hydroxychloroquine |
n.a. |
4/25 (16.0) |
| Cyclosporin A |
n.a. |
1/25 (4.0) |
| Anti-TNF therapy strategies |
n.a. |
0/25 (0.0) |
|
|
||
|
*p = 0.065, **p < 0.05, #p < 0.01, ##p < 0.001 for the comparison versus osteoarthritic patients. §Disease duration in OA patients is a rough estimate because the exact starting point is often not precisely known. Data are given as means ± SEM, percentages in parentheses, and ranges in square brackets. F/M, female/male; n.a., not applicable; NSAIDs, non-steroidal anti-inflammatory drugs; TNF, tumor necrosis factor. |
||
|
Schmidt et al. Arthritis Research & Therapy 2005 7:R938 doi:10.1186/ar1769 |
||
